Skip to Content

Repatha FDA Approval History

FDA Approved: Yes (First approved August 27, 2015)
Brand name: Repatha
Generic name: evolocumab
Dosage form: Injection
Company: Amgen Inc.
Treatment for: High Cholesterol; Prevention of Heart Attack and Stroke

Repatha (evolocumab) is a monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) indicated for the treatment of patients with heterozygous familial hypercholesterolemia; homozygous familial hypercholesterolemia; and to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.

Development Timeline for Repatha

Jan  7, 2019Amgen Makes All Repatha (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
Oct 24, 2018Amgen Makes Repatha (evolocumab) Available in the U.S. at a 60 Percent Reduced List Price
Dec  1, 2017Approval  FDA Approves Amgen's Repatha (evolocumab) to Prevent Heart Attack and Stroke
Jul 11, 2016Approval  FDA Approves Repatha (evolocumab) Pushtronex - First And Only Single Monthly Injection for a PCSK9 Inhibitor
Aug 27, 2015Approval  FDA Approves Repatha (evolocumab) to Treat Certain Patients with High Cholesterol
Apr 29, 2015Amgen Announces FDA Advisory Committee Meeting to Review Repatha (Evolocumab) for High Cholesterol
Mar 15, 2015Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha (Evolocumab)
Mar 14, 2015New Detailed Data From Phase 3 Study Show Amgen's Repatha (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo
Nov 10, 2014FDA Accepts Amgen's BLA For LDL Cholesterol-Lowering Medication Evolocumab
Aug 28, 2014Amgen Submits BLA For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.